ULK1 inhibitors and methods using same

Patent metadata

Field	Value
Publication number	US-10266549-B2
Application number	US-201515505532-A
Country	US
Kind code	B2
Filing date	Aug 25, 2015
Priority date	Aug 25, 2014
Publication date	Apr 23, 2019
Grant date	Apr 23, 2019

Abstract

In certain aspects, the invention provides a method for treating a disease or condition in a subject, the method comprising co-administering to a subject in need thereof a therapeutically effective amount of at least one ULK1-inhibiting pyrimidine, and a therapeutically effective amount of an mTOR inhibitor.

First claim

What is claimed is:

1. A compound, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:

2. The compound or pharmaceutically acceptable salt thereof of claim 1 , having the structure:

3. The compound or pharmaceutically acceptable salt thereof of claim 1 , having the structure:

4. The compound or pharmaceutically acceptable salt thereof of claim 1 , having the structure:

5. The compound or pharmaceutically acceptable salt thereof of claim 1 , having the structure:

6. The compound or pharmaceutically acceptable salt thereof of claim 1 , having the structure:

7. The compound or pharmaceutically acceptable salt thereof of claim 1 , having the structure:

8. The compound or pharmaceutically acceptable salt thereof of claim 1 , having the structure:

9. The compound or pharmaceutically acceptable salt thereof of claim 1 , having the structure:

10. The compound or pharmaceutically acceptable salt thereof of claim 1 , having the structure:

11. The compound or pharmaceutically acceptable salt thereof of claim 1 , having the structure:

12. The compound or pharmaceutically acceptable salt thereof of claim 1 , having the structure:

13. A compound or a pharmaceutically acceptable salt thereof having the structure:

14. A pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt thereof selected from the group consisting of:

and
at least one pharmaceutically acceptable additive.

15. The pharmaceutical composition of claim 14 , wherein the compound or the pharmaceutically acceptable salt thereof is selected from the group consisting of:

16. The pharmaceutical composition of claim 14 , wherein the compound or the pharmaceutically acceptable salt thereof is selected from the group consisting of:

17. The pharmaceutical composition of claim 14 , wherein the compound or the pharmaceutically acceptable salt thereof is selected from the group consisting of:

18. The pharmaceutical composition of claim 14 , wherein the compound or the pharmaceutically acceptable salt thereof is selected from the group consisting of:

19. The pharmaceutical composition of claim 14 , wherein the compound or the pharmaceutically acceptable salt thereof has the structure:

20. A pharmaceutical composition comprising:
a compound or a pharmaceutically acceptable salt thereof having the structure:

 and
at least one pharmaceutically acceptable additive.

Assignees

• Salk Inst For Biological Studi
• Sanford Burnham Prebys Medical Discovery Inst
• Univ Yale

Inventors

• Shaw Reuben J
• Egan Daniel F
• Cosford Nicholas
• Turk Benjamin
• Vamos Mitchell
• Panickar Dhanya Raveendra
• Chun Matthew
• Sheffler Douglas

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P35/04

  specific for metastasis · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P35/02

  specific for leukemia · CPC title